These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 29153588)
1. Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents. Labib MB; Philoppes JN; Lamie PF; Ahmed ER Bioorg Chem; 2018 Feb; 76():67-80. PubMed ID: 29153588 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents. Philoppes JN; Lamie PF Bioorg Chem; 2019 Aug; 89():102978. PubMed ID: 31136900 [TBL] [Abstract][Full Text] [Related]
3. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents. Hisham M; Youssif BGM; Osman EEA; Hayallah AM; Abdel-Aziz M Eur J Med Chem; 2019 Aug; 176():117-128. PubMed ID: 31108261 [TBL] [Abstract][Full Text] [Related]
6. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors. Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400 [TBL] [Abstract][Full Text] [Related]
8. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy. Altıntop MD; Ertorun İ; Akalın Çiftçi G; Özdemir A Eur J Med Chem; 2024 Oct; 276():116698. PubMed ID: 39047611 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743 [TBL] [Abstract][Full Text] [Related]
13. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation. Warda ET; Shehata IA; El-Ashmawy MB; El-Gohary NS Bioorg Med Chem; 2020 Nov; 28(21):115674. PubMed ID: 33065442 [TBL] [Abstract][Full Text] [Related]
14. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study. AboulWafa OM; Daabees HMG; Badawi WA Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]
17. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. Soliman AM; Alqahtani AS; Ghorab M J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303 [TBL] [Abstract][Full Text] [Related]
19. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors. Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]